FDA: improved artificial heart valve approved

FDA: improved artificial heart valve approved

(HealthDay)—The newest version of the Sapien 3 Transcatheter Heart Valve has been approved by the U.S. Food and Drug Administration.

The artificial valve is designed for patients with . The product is sanctioned for people who are inoperable or at high risk for death or complications from , the FDA said in a news release.

The newly approved device is the third-generation Sapien 3, originally approved in 2011. The newest version includes changes designed to minimize leakage, the FDA said. Possible side effects of the device itself include stroke, , heart attack, bleeding, the need for a pacemaker, or death.

The device isn't recommended for people who can't tolerate anticoagulation/antiplatelet therapy, the agency said. The Sapien 3 is manufactured by Edwards Lifesciences, based in Irvine, Calif.

More information: More Information

Health News Copyright © 2015 HealthDay. All rights reserved.

Citation: FDA: improved artificial heart valve approved (2015, June 19) retrieved 24 April 2024 from https://medicalxpress.com/news/2015-06-fda-artificial-heart-valve.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Approval expanded for sapien artificial heart valve

7 shares

Feedback to editors